Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Symann

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
ESTIC position paper: high-dose chemotherapy for breast cancer, investigation should continueJ Crown, B Coiffier, H Cortés-Funes, et al.
European Journal of Cancer & Clinical Oncology|February 1, 1988
Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodiesJ L Canon, Y Humblet, A M Lebacq-Verheyden, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1990
Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual diseaseA Bosly, P Brice, Y Humblet, et al.
Annals of Hematology|May 10, 2000
Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patientsB Vandercam, J Gérain, Y Humblet, et al.
Cancer Genetics and Cytogenetics|June 1, 1984
Translocation t(3;17)(q26;q22): a marker of acute disease in myeloproliferative disorders?C Mecucci, J L Michaux, A Broeckaert-Van Orshoven, et al.
Experimental Hematology|September 1, 1992
Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumorsA Bosly, T Guillaume, P Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized studyY Humblet, M Symann, A Bosly, et al.
Cytokines, Cellular & Molecular Therapy|March 1, 1997
Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assaysL D'Hondt, M André, T Guillaume, et al.
Leukemia & Lymphoma|June 1, 1999
The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failedL D'Hondt, R V Emmons, M André, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II studyH von der Maase, P Geertsen, N Thatcher, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
ESTIC position paper: high-dose chemotherapy for breast cancer, investigation should continueJ Crown, B Coiffier, H Cortés-Funes, et al.
European Journal of Cancer & Clinical Oncology|February 1, 1988
Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodiesJ L Canon, Y Humblet, A M Lebacq-Verheyden, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1990
Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual diseaseA Bosly, P Brice, Y Humblet, et al.
Annals of Hematology|May 10, 2000
Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patientsB Vandercam, J Gérain, Y Humblet, et al.
Cancer Genetics and Cytogenetics|June 1, 1984
Translocation t(3;17)(q26;q22): a marker of acute disease in myeloproliferative disorders?C Mecucci, J L Michaux, A Broeckaert-Van Orshoven, et al.
Experimental Hematology|September 1, 1992
Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumorsA Bosly, T Guillaume, P Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized studyY Humblet, M Symann, A Bosly, et al.
Cytokines, Cellular & Molecular Therapy|March 1, 1997
Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assaysL D'Hondt, M André, T Guillaume, et al.
Leukemia & Lymphoma|June 1, 1999
The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failedL D'Hondt, R V Emmons, M André, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II studyH von der Maase, P Geertsen, N Thatcher, et al.
Pageof 9